<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01000727</url>
  </required_header>
  <id_info>
    <org_study_id>480848/033</org_study_id>
    <nct_id>NCT01000727</nct_id>
  </id_info>
  <brief_title>The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial</brief_title>
  <acronym>SOLID-TIMI 52</acronym>
  <official_title>A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects Following Acute Coronary Syndrome to Compare the Incidence of Major Adverse Cardiovascular Events (MACE).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The TIMI Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test whether darapladib can safely lower the chances of having a
      cardiovascular event (such as a heart attack or urgent coronary revascularization (e.g.
      medical procedures performed to restore the normal blood flow in patients with
      atherosclerosis)) when treatment is started within 30 days after an acute coronary syndrome
      (also called ACS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects who qualify for the study will be randomized 1:1 to either darapladib or placebo
      administered in addition to standard therapy. Following the baseline visit, subjects will be
      expected to return for clinic visits at 1 month, 3 months, 6 months and every 6 months until
      the end of the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1, 2009</start_date>
  <completion_date type="Actual">April 24, 2014</completion_date>
  <primary_completion_date type="Actual">April 1, 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With First Occurrence of Any Event in the Composite of Major Coronary Events During the Time Period for Follow-up (FU) of Cardiovascular (CV) Event</measure>
    <time_frame>From randomization until the End-of-Treatment visit or the last date on which endpoints were able to be assessed (up to 3.80 years)</time_frame>
    <description>Coronary heart disease (CHD) death=occurrence of a fatal myocardial infarction (MI), death caused by documented cardiac arrest, death resulting from heart failure in a participant with known CHD, death from other forms of acute/chronic CHD, unwitnessed death of unknown origin, or sudden death. Acute MI=evidence of myocardial necrosis in a clinical setting consistent with myocardial ischemia. Prior MI diagnosed post-randomization (e.g., silent MI)=the development of new pathological Q waves with/without symptoms OR imaging evidence of a region of loss of viable myocardium that is thinned and fails to contract, in the absence of a nonischemic cause (pre-event imaging data required for verification of new abnormality), OR pathological findings of a healed/healing MI. Urgent coronary revascularization (CR) for MI=ischemic discomfort at rest that prompted CR during the same hospitalization or resulted in hospital transfer for the purpose of CR.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With First Occurrence of Any Component of the Composite of Major Adverse Cardiovascular Events (Cardiovascular [CV] Death, Non-fatal MI or Non-fatal Stroke) During the Time Period for Follow-up of CV Events</measure>
    <time_frame>From randomization until the End-of-Treatment visit or the last date on which endpoints were able to be assessed (up to 3.80 years)</time_frame>
    <description>CV death=death due to a CV cause, which included but was not limited to deaths resulting from stroke, arrhythmia, sudden death (witnessed/unwitnessed), MI, heart failure, pulmonary embolism, peripheral arterial disease, or complications of a CV procedure. Deaths not clearly attributable to non-CV causes are considered to be CV deaths. Acute MI=evidence of myocardial necrosis in a clinical setting consistent with myocardial ischemia. Prior MI diagnosed post-randomization (e.g., silent MI)=the development of new pathological Q waves with/without symptoms OR imaging evidence of a region of loss of viable myocardium that is thinned and fails to contract, in the absence of a non-ischemic cause (pre-event imaging data required for verification of new abnormality), OR pathological findings of a healed/healing MI. Stroke=presence of a new focal neurologic deficit thought to be of vascular origin, with signs/symptoms lasting &gt;24 hours or results in death (in &lt;24 hours).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cardiovascular Death During the Time Period for Follow-up of Cardiovascular Events</measure>
    <time_frame>From randomization until the End-of-Treatment visit or the last date on which endpoints were able to be assessed (up to 3.80 years)</time_frame>
    <description>CV death is defined as a death due to a CV cause, which includes but is not limited to deaths resulting from stroke, arrhythmia, sudden death (witnessed/unwitnessed), MI, heart failure, pulmonary embolism, peripheral arterial disease, or complications of a CV procedure. Deaths not clearly attributable to non-CV causes are considered to be CV deaths.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With First Occurrence of MI (Fatal/Nonfatal) During the Time Period for Follow-up of Cardiovascular Events</measure>
    <time_frame>From randomization until the End-of-Treatment visit or the last date on which endpoints were able to be assessed (up to 3.80 years)</time_frame>
    <description>Acute MI is defined as evidence of myocardial necrosis in a clinical setting consistent with myocardial ischemia. Prior MI diagnosed post-randomization (e.g., silent MI)=the development of new pathological Q waves with/without symptoms OR imaging evidence of a region of loss of viable myocardium that is thinned and fails to contract, in the absence of a non-ischemic cause (pre-event imaging data required for verification of new abnormality), OR pathological findings of a healed/healing MI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With First Occurrence of Stroke (Fatal/Non-fatal) During the Time Period for Follow-up of Cardiovascular Events</measure>
    <time_frame>From randomization until the End-of-Treatment visit or the last date on which endpoints were able to be assessed (up to 3.80 years)</time_frame>
    <description>Stroke is defined as the presence of a new focal neurologic deficit thought to be of vascular origin, with signs/symptoms lasting &gt;24 hours or results in death (in &lt;24 hours).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With CHD Death During the Time Period for Follow-up of Cardiovascular Events</measure>
    <time_frame>From randomization until the End-of-Treatment visit or the last date on which endpoints were able to be assessed (up to 3.80 years)</time_frame>
    <description>CHD death is defined as the occurrence of a fatal MI, death caused by documented cardiac arrest, death resulting from heart failure in a participant with known CHD, death from other forms of acute/chronic CHD, unwitnessed death of unknown origin, or sudden death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Urgent Coronary Revascularization for Myocardial Ischemia During the Time Period for Follow-up of Cardiovascular Events</measure>
    <time_frame>From randomization until the End-of-Treatment visit or the last date on which endpoints were able to be assessed (up to 3.80 years)</time_frame>
    <description>Urgent coronary revascularization for myocardial ischemia is defined as ischemic discomfort at rest that prompts coronary revascularization (PCI or coronary artery bypass graft [CABG]) during the same hospitalization or resulting in hospital transfer for the purpose of coronary revascularization. PCI is defined as any attempt at revascularization even if not successful (e.g., angioplasty, atherectomy or stenting).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With First Occurrence of Any Event in the Composite of Total Coronary Events (CHD Death, Non-fatal MI, Hospitalization for Unstable Angina, or Any Coronary Revascularization Procedure) During the Time Period for FU of CV Events</measure>
    <time_frame>From randomization until the End-of-Treatment visit or the last date on which endpoints were able to be assessed (up to 3.80 years)</time_frame>
    <description>CHD death, acute MI, and prior MI diagnosed post-randomization are defined in the primary endpoint (major coronary events). Hospitalization for unstable angina=one of the following, but not fulfilling the criteria for MI: ischemic discomfort at rest associated with electrocardiogram (ECG) changes leading to hospitalization; ischemic discomfort at rest regardless of ECG changes leading to hospitalization and revascularization during the same admission; ischemic discomfort at rest in hospital associated with ECG changes; ischemic discomfort at rest in hospital without ECG changes resulting in revascularization during the same admission. NOTE: The event was not considered to be unstable angina if, after invasive/non-invasive testing or other diagnostic testing, the discomfort was found not to be caused by myocardial ischemia. Coronary revascularization procedures exclude PCI planned prior to randomization but performed after randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With First Occurrence of Any Coronary Revascularization Procedures (Excluding Coronary Revascularization Planned Prior to Randomization, But Performed After Randomization) During the Time Period for Follow-up of Cardiovascular Event</measure>
    <time_frame>From randomization until the End-of-Treatment visit or the last date on which endpoints were able to be assessed (up to 3.80 years)</time_frame>
    <description>All coronary revascularization procedures (except for PCI planned prior to randomization but performed after randomization) are included. Examples include coronary artery bypass graft, balloon angioplasty and stenting. The number of participants, with first occurrence of any coronary revascularization procedures, were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With First Occurrence of Any Component of the Composite of All-cause Mortality, Non-fatal MI, or Nonfatal Stroke During the Time Period for Follow-up of Cardiovascular Events</measure>
    <time_frame>From randomization until the End-of-Treatment visit or the last date on which endpoints were able to be assessed (up to 3.80 years)</time_frame>
    <description>Acute MI is defined as evidence of myocardial necrosis in a clinical setting consistent with myocardial ischemia. Prior MI diagnosed post-randomization (e.g., silent MI)=the development of new pathological Q waves with/without symptoms OR imaging evidence of a region of loss of viable myocardium that is thinned and fails to contract, in the absence of a non-ischemic cause (pre-event imaging data required for verification of new abnormality), OR pathological findings of a healed/healing MI. Stroke=presence of a new focal neurologic deficit thought to be of vascular origin, with signs/symptoms lasting &gt;24 hours or results in death (in &lt;24 hours).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With First Occurrence of Any Event in the Composite of CHD Death and Non-fatal MI During the Time Period for Follow-up of Cardiovascular Events</measure>
    <time_frame>From randomization until the End-of-Treatment visit or the last date on which endpoints were able to be assessed (up to 3.80 years)</time_frame>
    <description>Acute MI is defined as evidence of myocardial necrosis in a clinical setting consistent with myocardial ischemia. Prior MI diagnosed post-randomization (e.g., silent MI)=the development of new pathological Q waves with/without symptoms OR imaging evidence of a region of loss of viable myocardium that is thinned and fails to contract, in the absence of a non-ischemic cause (pre-event imaging data required for verification of new abnormality), OR pathological findings of a healed/healing MI. CHD death is defined as the occurrence of a fatal MI, death caused by documented cardiac arrest, death resulting from heart failure in a participant with known CHD, death from other forms of acute/chronic CHD, unwitnessed death of unknown origin, or sudden death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All-cause Mortality During the Time Period for Vital Status</measure>
    <time_frame>From randomization until the End-of-Treatment visit or the last date on which endpoints were able to be assessed (up to 3.80 years)</time_frame>
    <description>Number of participants who died, during the vital status time-period were reported. The participants who were known to have died, date of death was used; for participants who completed the study the study completion date was used; for participants who withdrew from the study where vital status was ascertained , and are known to have not died , the last known date to be alive was used and for participants whom vital status was not ascertained, following study withdrawal the study withdrawal date was used.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13026</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Darapladib 160 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single daily oral tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single daily oral tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darapladib 160 mg</intervention_name>
    <description>Lp-PLA2 inhibitor</description>
    <arm_group_label>Darapladib 160 mg</arm_group_label>
    <other_name>SB-480848</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard Therapy</intervention_name>
    <description>Guideline mandated therapy for individual's condition</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Darapladib 160 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed written informed consent.

          -  Men or women at least 18 years old (in Taiwan, at least 20 years old). Women must be
             post-menopausal or using a highly effective method for avoidance of pregnancy.

          -  Hospitalization for acute coronary syndrome (ACS) within 30 days prior to study entry.

          -  Clinically stable for 24 hours prior to study entry.

          -  A planned percutaneous coronary intervention (PCI) should be performed prior to study
             entry, whenever possible.

          -  At least one of the following:

          -  At least 60 years old.

          -  Myocardial infarction prior to the qualifying ACS event.

          -  Diabetes mellitus requiring treatment with medication.

          -  Diagnosed mild or moderate reduction in kidney function.

          -  Cerebrovascular disease (carotid artery disease or ischemic stroke more than 3 months
             prior to study entry) OR peripheral artery disease.

        Exclusion Criteria:

          -  ACS symptoms or lab results not believed to be caused by a narrowing or blocked
             coronary artery.

          -  No major coronary artery with a blockage of more than 50% (unless all stenoses are
             successfully treated by PCI).

          -  Planned coronary artery bypass graft (CABG) surgery, or CABG surgery performed after
             the qualifying ACS event and prior to study entry.

          -  Certain types of liver disease.

          -  Severe reduction in kidney function OR removal of a kidney OR kidney transplant.

          -  Severe heart failure.

          -  Blood pressure higher than normal despite lifestyle changes and treatment with
             medications.

          -  Any life-threatening disease with a life expectancy of less than 2 years (other than
             heart disease) that may prevent the subject from completing the study.

          -  Severe asthma that is poorly controlled with medication.

          -  Pregnancy (Note: A pregnancy test will be performed on all non-sterile women prior to
             study entry).

          -  Previous severe allergic reaction to food, medications, drink, insect stings, etc.

          -  Drug or alcohol abuse within the past 6 months. Mental/psychological impairment that
             may prevent the subject from complying with study procedures or understanding the goal
             and potential risks of participating in the study.

          -  Certain medications that may interfere with the study medication (these will be
             identified by the study doctor).

          -  If both birth parents are at least 50% Japanese, Chinese, or Korean ancestry, must
             have a blood sample collected for Lp-PLA2 activity. Those with Lp-PLA2 activity less
             than or equal to 20.0 nmol/min/mL are excluded.

          -  Previously took darapladib (SB-480848).

          -  Participation in a study of an investigational medication within the past 30 days.

          -  Current participation in a study of an investigational device.

          -  Any other reason the investigator deems the subject should not participate in the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <zip>99508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cottonwood</city>
        <state>Arizona</state>
        <zip>86326</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fort Smith</city>
        <state>Arkansas</state>
        <zip>72903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93721</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lomita</city>
        <state>California</state>
        <zip>90717</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Los Alamitos</city>
        <state>California</state>
        <zip>90720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mission Hills</city>
        <state>California</state>
        <zip>91345</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95661</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stockton</city>
        <state>California</state>
        <zip>95204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Thousand Oaks</city>
        <state>California</state>
        <zip>91360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Golden</city>
        <state>Colorado</state>
        <zip>80401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Greeley</city>
        <state>Colorado</state>
        <zip>80631</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Littleton</city>
        <state>Colorado</state>
        <zip>80120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wheat Ridge</city>
        <state>Colorado</state>
        <zip>80033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bridgeport</city>
        <state>Connecticut</state>
        <zip>06606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bridgeport</city>
        <state>Connecticut</state>
        <zip>06610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Guilford</city>
        <state>Connecticut</state>
        <zip>06437</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Atlantis</city>
        <state>Florida</state>
        <zip>33462</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fleming Island</city>
        <state>Florida</state>
        <zip>32003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gulf Breeze</city>
        <state>Florida</state>
        <zip>32561</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Inverness</city>
        <state>Florida</state>
        <zip>34452</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jacksonville Beach</city>
        <state>Florida</state>
        <zip>32250</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <zip>33458</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <zip>34741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <zip>33025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Palm Beach Gardens</city>
        <state>Florida</state>
        <zip>33410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33317</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33952</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Safety Harbor</city>
        <state>Florida</state>
        <zip>34695</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Trinity</city>
        <state>Florida</state>
        <zip>34655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vero Beach</city>
        <state>Florida</state>
        <zip>32960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wellington</city>
        <state>Florida</state>
        <zip>33449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cumming</city>
        <state>Georgia</state>
        <zip>30041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aurora</city>
        <state>Illinois</state>
        <zip>60504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bannockburn</city>
        <state>Illinois</state>
        <zip>60015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Melrose Park</city>
        <state>Illinois</state>
        <zip>60160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mokena</city>
        <state>Illinois</state>
        <zip>60448</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>North Chicago</city>
        <state>Illinois</state>
        <zip>60064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oakbrook Terrace</city>
        <state>Illinois</state>
        <zip>60181</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Park Ridge</city>
        <state>Illinois</state>
        <zip>60068</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rock Island</city>
        <state>Illinois</state>
        <zip>61201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Avon</city>
        <state>Indiana</state>
        <zip>46123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hammond</city>
        <state>Indiana</state>
        <zip>46320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Muncie</city>
        <state>Indiana</state>
        <zip>47303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Munster</city>
        <state>Indiana</state>
        <zip>46321</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46601-1066</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Valparaiso</city>
        <state>Indiana</state>
        <zip>46383</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50266</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Crestview Hills</city>
        <state>Kentucky</state>
        <zip>41017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536-0294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Alexandria</city>
        <state>Louisiana</state>
        <zip>71301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lafayette</city>
        <state>Louisiana</state>
        <zip>70506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <zip>70601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lewiston</city>
        <state>Maine</state>
        <zip>04240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bel Air</city>
        <state>Maryland</state>
        <zip>21014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Columbia</city>
        <state>Maryland</state>
        <zip>21044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salisbury</city>
        <state>Maryland</state>
        <zip>21801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ayer</city>
        <state>Massachusetts</state>
        <zip>01432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fall River</city>
        <state>Massachusetts</state>
        <zip>02720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01199</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dearborn</city>
        <state>Michigan</state>
        <zip>48124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48532</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Marquette</city>
        <state>Michigan</state>
        <zip>49855</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pontiac</city>
        <state>Michigan</state>
        <zip>48341-2985</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48085</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ypsilanti</city>
        <state>Michigan</state>
        <zip>48197</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <zip>55805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55426</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Robbinsdale</city>
        <state>Minnesota</state>
        <zip>55422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint Cloud</city>
        <state>Minnesota</state>
        <zip>56303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Joplin</city>
        <state>Missouri</state>
        <zip>64804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Columbia Falls</city>
        <state>Montana</state>
        <zip>65201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Great Falls</city>
        <state>Montana</state>
        <zip>59405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kalispell</city>
        <state>Montana</state>
        <zip>59901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Grand Island</city>
        <state>Nebraska</state>
        <zip>68803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Papillion</city>
        <state>Nebraska</state>
        <zip>68046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Browns Mills</city>
        <state>New Jersey</state>
        <zip>08015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Elizabeth</city>
        <state>New Jersey</state>
        <zip>07202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Elmer</city>
        <state>New Jersey</state>
        <zip>8318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Haddon Heights</city>
        <state>New Jersey</state>
        <zip>08035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Linden</city>
        <state>New Jersey</state>
        <zip>07036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paterson</city>
        <state>New Jersey</state>
        <zip>07503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pomona</city>
        <state>New Jersey</state>
        <zip>8240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sewell</city>
        <state>New Jersey</state>
        <zip>08080</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Somerset</city>
        <state>New Jersey</state>
        <zip>08873</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Summit</city>
        <state>New Jersey</state>
        <zip>07902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <zip>08043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>West Orange</city>
        <state>New Jersey</state>
        <zip>07052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Peekskill</city>
        <state>New York</state>
        <zip>10567</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Roslyn</city>
        <state>New York</state>
        <zip>11576</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>The Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Troy</city>
        <state>New York</state>
        <zip>12180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Williamsville</city>
        <state>New York</state>
        <zip>14221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Burlington</city>
        <state>North Carolina</state>
        <zip>27215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Concord</city>
        <state>North Carolina</state>
        <zip>28025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gastonia</city>
        <state>North Carolina</state>
        <zip>28054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <zip>28078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Matthews</city>
        <state>North Carolina</state>
        <zip>28105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Monroe</city>
        <state>North Carolina</state>
        <zip>28112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pinehurst</city>
        <state>North Carolina</state>
        <zip>28374</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rocky Mount</city>
        <state>North Carolina</state>
        <zip>27804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sanford</city>
        <state>North Carolina</state>
        <zip>27330</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Grand Forks</city>
        <state>North Dakota</state>
        <zip>58201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Elyria</city>
        <state>Ohio</state>
        <zip>44035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fairfield</city>
        <state>Ohio</state>
        <zip>45014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fairview Park</city>
        <state>Ohio</state>
        <zip>44126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lorain</city>
        <state>Ohio</state>
        <zip>44053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mansfield</city>
        <state>Ohio</state>
        <zip>44906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oakbrook Terrace</city>
        <state>Ohio</state>
        <zip>60181</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sandusky</city>
        <state>Ohio</state>
        <zip>44870</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Youngstown</city>
        <state>Ohio</state>
        <zip>44501-1790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Zanesville</city>
        <state>Ohio</state>
        <zip>43701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Midwest City</city>
        <state>Oklahoma</state>
        <zip>73110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Beaver</city>
        <state>Pennsylvania</state>
        <zip>15009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Camp Hill</city>
        <state>Pennsylvania</state>
        <zip>17011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chambersburg</city>
        <state>Pennsylvania</state>
        <zip>17201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Doylestown</city>
        <state>Pennsylvania</state>
        <zip>18901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jenkintown</city>
        <state>Pennsylvania</state>
        <zip>19046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jersey Shore</city>
        <state>Pennsylvania</state>
        <zip>17740</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <zip>17604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lansdale</city>
        <state>Pennsylvania</state>
        <zip>19446</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leetsdale</city>
        <state>Pennsylvania</state>
        <zip>15056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sayre</city>
        <state>Pennsylvania</state>
        <zip>18840</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Scranton</city>
        <state>Pennsylvania</state>
        <zip>18501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sellersville</city>
        <state>Pennsylvania</state>
        <zip>18960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>West Chester</city>
        <state>Pennsylvania</state>
        <zip>19380</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>York</city>
        <state>Pennsylvania</state>
        <zip>17405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Columbia</city>
        <state>Tennessee</state>
        <zip>38401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38085</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Johnson City</city>
        <state>Tennessee</state>
        <zip>37604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oak Ridge</city>
        <state>Tennessee</state>
        <zip>37830</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-8887</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555-0553</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Harker Heights</city>
        <state>Texas</state>
        <zip>76548</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Katy</city>
        <state>Texas</state>
        <zip>77493</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kingwood</city>
        <state>Texas</state>
        <zip>77339</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78681</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Marcos</city>
        <state>Texas</state>
        <zip>78666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Victoria</city>
        <state>Texas</state>
        <zip>77901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Midlothian</city>
        <state>Virginia</state>
        <zip>23114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Winchester</city>
        <state>Virginia</state>
        <zip>22601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bellingham</city>
        <state>Washington</state>
        <zip>98225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Burien</city>
        <state>Washington</state>
        <zip>98166</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Everett</city>
        <state>Washington</state>
        <zip>98201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kirkland</city>
        <state>Washington</state>
        <zip>98034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204-2334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Walla Walla</city>
        <state>Washington</state>
        <zip>99362</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Beloit</city>
        <state>Wisconsin</state>
        <zip>53511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wausau</city>
        <state>Wisconsin</state>
        <zip>54401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Capital Federal</city>
        <state>Buenos Aires</state>
        <zip>C1180AAX</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <state>Buenos Aires</state>
        <zip>C1179AAB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <state>Buenos Aires</state>
        <zip>C1425AST</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mar del Plata</city>
        <state>Buenos Aires</state>
        <zip>B7600FZN</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ramos Mejia</city>
        <state>Buenos Aires</state>
        <zip>B1704ETD</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Justo</city>
        <state>Buenos Aires</state>
        <zip>B1754FPI</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Nicolas</city>
        <state>Buenos Aires</state>
        <zip>B2900DMH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cordoba</city>
        <state>Crdova</state>
        <zip>X5000AAW</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cordoba</city>
        <state>Crdova</state>
        <zip>X5000EPU</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>2002</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S2000BIF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S2000CVD</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S2000ODA</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S2002OUR</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1425</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cipolletti</city>
        <zip>R8324CVM</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <zip>C1181ACH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Corrientes</city>
        <zip>W3400AMZ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Haedo, Buenos Aires</city>
        <zip>B1706AJU</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Miguel de Tucuman</city>
        <zip>T4000IFL</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santa fe</city>
        <zip>3000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sante Fe</city>
        <zip>S3000FSO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sante Fe</city>
        <zip>S3000GCI</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tucuman</city>
        <zip>T4000ICL</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Zrate</city>
        <zip>B2800DGH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Garran</city>
        <state>Australian Capital Territory</state>
        <zip>2606</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gosford</city>
        <state>New South Wales</state>
        <zip>2250</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Auchenflower</city>
        <state>Queensland</state>
        <zip>4066</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Milton</city>
        <state>Queensland</state>
        <zip>4064</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Elizabeth Vale</city>
        <state>South Australia</state>
        <zip>5112</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hobart</city>
        <state>Tasmania</state>
        <zip>7000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nedlands</city>
        <state>Victoria</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fremantle</city>
        <state>Western Australia</state>
        <zip>6160</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ashford</city>
        <zip>5035</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bonheiden</city>
        <zip>2820</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>La Louvire</city>
        <zip>7100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lige</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Roeselaere</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salvador</city>
        <state>Baha</state>
        <zip>41810010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fortaleza</city>
        <state>Cear</state>
        <zip>60864-190</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Goinia - GO</city>
        <state>Gois</state>
        <zip>74605-020</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Belo Horizonte</city>
        <state>Minas Gerais</state>
        <zip>30130-110</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Belo Horizonte</city>
        <state>Minas Gerais</state>
        <zip>30150-221.</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Campina Grande do Sul</city>
        <state>Paran</state>
        <zip>83430000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Curitiba</city>
        <state>Paran</state>
        <zip>80730-150</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pelotas</city>
        <state>Rio Grande Do Sul</state>
        <zip>96015-290</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90020-090</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90610000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90620001</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90880-480</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>91350-200</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Natal</city>
        <state>Rio Grande Du Norte</state>
        <zip>59020-100</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Marlia</city>
        <state>So Paulo</state>
        <zip>17515-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sao Jose do Rio Preto</city>
        <state>So Paulo</state>
        <zip>15090-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sao Paulo</city>
        <state>So Paulo</state>
        <zip>04024-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>So Jos do Rio Preto</city>
        <state>So Paulo</state>
        <zip>15015210</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Votuporanga</city>
        <state>So Paulo</state>
        <zip>15500-003</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bahia</city>
        <zip>40050-410</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Braslia</city>
        <zip>70658-700</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Campinas</city>
        <zip>13060-803</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Campo Grande</city>
        <zip>79080-090</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>21041-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rio De Janeiro</city>
        <zip>RJ 22240-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>So Paulo - SP</city>
        <zip>01323-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>So Paulo</city>
        <zip>04012-180</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>So Paulo</city>
        <zip>05403000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>So Paulo</city>
        <zip>05508-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Uberlandia</city>
        <zip>38400-902</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dimitrovgrad</city>
        <zip>6400</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Haskovo</city>
        <zip>6300</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Plovdiv</city>
        <zip>4003</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sofia</city>
        <zip>1000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sofia</city>
        <zip>1202</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sofia</city>
        <zip>1407</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sofia</city>
        <zip>1527</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sofia</city>
        <zip>1709</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Veliko Tarnovo</city>
        <zip>5000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Campbell River</city>
        <state>British Columbia</state>
        <zip>V9W 5Y4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New Westminister</city>
        <state>British Columbia</state>
        <zip>V3L 3W4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3V 1N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8R 4R2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Truro</city>
        <state>Nova Scotia</state>
        <zip>B2N 1L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ajax</city>
        <state>Ontario</state>
        <zip>L1S 7K8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6Z 4N5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cambridge</city>
        <state>Ontario</state>
        <zip>N1R 6V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cambridge</city>
        <state>Ontario</state>
        <zip>N1R 7R1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kelowna</city>
        <state>Ontario</state>
        <zip>V1Y 1E4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5B 2P7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 8C3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1J 2J9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1J 2K1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4W7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sarnia</city>
        <state>Ontario</state>
        <zip>N7T 4X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3C 1S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3E 3B8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Thunder Bay</city>
        <state>Ontario</state>
        <zip>P7B 7C7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4C 3E7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5C 2T2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>JAV 2GB</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Longueuil</city>
        <state>Quebec</state>
        <zip>J4M 2X1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 3Y7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3G 1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Thetford Mines</city>
        <state>Quebec</state>
        <zip>G6G 2V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Temuco</city>
        <state>Regin De La Araucania</state>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Concepcin</city>
        <state>Regin Del Biobio</state>
        <zip>56-41</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Talcahuano</city>
        <state>Regin Del Biobio</state>
        <zip>427 0918</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santiago</city>
        <state>Regin Metro De Santiago</state>
        <zip>750 0922</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santiago</city>
        <state>Regin Metro De Santiago</state>
        <zip>7650018</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santiago</city>
        <state>Regin Metro De Santiago</state>
        <zip>8330024</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Via del Mar</city>
        <state>Valparaso</state>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santiago</city>
        <zip>8207257</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santiago</city>
        <zip>8900085</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Temuco</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <zip>730030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Haikou</city>
        <state>Hainan</state>
        <zip>570102</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <zip>116027</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Xian</city>
        <state>Shaanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250033</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Beijing</city>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Beijing</city>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Beijing</city>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Beijing</city>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Beijing</city>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hangzhou</city>
        <zip>310016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jinan</city>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200065</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Suzhou</city>
        <zip>215004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Armenia</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barranquilla</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bogota</city>
        <zip>38007</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bogota</city>
        <zip>5600520</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bogot</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bucaramanga</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cartagena</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manizales</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Medellin</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Medelln</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brno</city>
        <zip>656 91</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Caslav</city>
        <zip>286 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jihlava</city>
        <zip>586 33</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kromeriz</city>
        <zip>767 55</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Milevsko</city>
        <zip>399 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Olomouc</city>
        <zip>775 20</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Plzen - Bory</city>
        <zip>305 99</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Praha 10</city>
        <zip>100 34</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Praha 2</city>
        <zip>128 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Slany</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Svitavy</city>
        <zip>568 25</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Usti nad Orlici</city>
        <zip>562 18</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Zlin</city>
        <zip>762 75</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aalborg</city>
        <zip>DK-9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aarhus</city>
        <zip>DK-8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Esbjerg</city>
        <zip>6700</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Frederikssund</city>
        <zip>DK-3600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Glostrup</city>
        <zip>DK-2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Herlev</city>
        <zip>DK-2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Holbk</city>
        <zip>DK-4300</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hvidovre</city>
        <zip>DK-2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Koebenhavn N</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kolding</city>
        <zip>DK-6000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kbenhavn NV</city>
        <zip>DK-2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kbenhavn S</city>
        <zip>DK-2300</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kge</city>
        <zip>DK-4600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nstved</city>
        <zip>4700</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Odense C</city>
        <zip>DK-5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Silkeborg</city>
        <zip>DK-8600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Svendborg</city>
        <zip>5700</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pau</city>
        <state>Aquitaine</state>
        <zip>64046</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Langres</city>
        <state>Champagne-Ardenne</state>
        <zip>52206</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dunkerque</city>
        <state>Nord-Pas-de-Calais</state>
        <zip>59240</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Avignon</city>
        <zip>84000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Besanon Cedex</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Crteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dijon Cedex</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lagny sur Marne</city>
        <zip>77405</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Le Plessis Robinson</city>
        <zip>92350</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Marseille Cedex 08</city>
        <zip>13285</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montfermeil</city>
        <zip>93370</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paris Cedex 18</city>
        <zip>75877</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Quincy sous Snart</city>
        <zip>91480</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Strasbourg Cedex</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toulouse</city>
        <zip>31500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tourcoing</city>
        <zip>59200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Valenciennes</city>
        <zip>59300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bad Krozingen</city>
        <state>Baden-Wuerttemberg</state>
        <zip>79189</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stuttgart</city>
        <state>Baden-Wuerttemberg</state>
        <zip>70376</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ulm</city>
        <state>Baden-Wuerttemberg</state>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>81737</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bad Nauheim</city>
        <state>Hessen</state>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Darmstadt</city>
        <state>Hessen</state>
        <zip>64283</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>65929</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Langen</city>
        <state>Hessen</state>
        <zip>63225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Limburg</city>
        <state>Hessen</state>
        <zip>65549</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bad Rothenfelde</city>
        <state>Niedersachsen</state>
        <zip>49214</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oldenburg</city>
        <state>Niedersachsen</state>
        <zip>26133</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bielefeld</city>
        <state>Nordrhein-Westfalen</state>
        <zip>33604</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Eschweiler</city>
        <state>Nordrhein-Westfalen</state>
        <zip>52249</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45359</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Neuss</city>
        <state>Nordrhein-Westfalen</state>
        <zip>41464</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wuppertal</city>
        <state>Nordrhein-Westfalen</state>
        <zip>42117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ludwigshafen</city>
        <state>Rheinland-Pfalz</state>
        <zip>67063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Homburg</city>
        <state>Saarland</state>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Luebeck</city>
        <state>Schleswig-Holstein</state>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Altenburg</city>
        <state>Thueringen</state>
        <zip>04600</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>12351</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>12559</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bremen</city>
        <zip>28277</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Halle</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Budapest</city>
        <zip>1032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Budapest</city>
        <zip>1096</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Budapest</city>
        <zip>1106</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Budapest</city>
        <zip>1125</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Budapest</city>
        <zip>1134</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Budapest</city>
        <zip>1145</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cegld</city>
        <zip>2700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Eger</city>
        <zip>3300</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gyula</city>
        <zip>5700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hodmezovasarhely</city>
        <zip>6800</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kistarcsa</city>
        <zip>2143</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Miskolc</city>
        <zip>3526</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Szolnok</city>
        <zip>5004</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Szombathely</city>
        <zip>9700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Szkesfehrvr</city>
        <zip>8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Zalaegerszeg</city>
        <zip>8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ahmedabad</city>
        <zip>380052</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ahmedabad</city>
        <zip>380060</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Amritsar</city>
        <zip>143004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chennai</city>
        <zip>600037</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chennai</city>
        <zip>600081</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Faridabad</city>
        <zip>121001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gandhinagar</city>
        <zip>382428</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gurgaon</city>
        <zip>122001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hyderabad</city>
        <zip>500001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hyderabad</city>
        <zip>500020</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hyderabad</city>
        <zip>500033</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hyderabad</city>
        <zip>500063</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hyderabad</city>
        <zip>500082</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Indore</city>
        <zip>452018</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jaipur</city>
        <zip>302017</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lucknow</city>
        <zip>226014</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mohali</city>
        <zip>160062</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New Delhi</city>
        <zip>110025</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New Delhi</city>
        <zip>110060</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New Delhi</city>
        <zip>110070</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Noida</city>
        <zip>201301</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Patiala</city>
        <zip>147001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pune,</city>
        <zip>411001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pune</city>
        <zip>411004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Secunderabad,</city>
        <zip>500003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vadodara</city>
        <zip>390015</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Visakhapatnam</city>
        <zip>530002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ashkelon</city>
        <zip>78278</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Beer Sheva</city>
        <zip>84350</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Haddera</city>
        <zip>38100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Haifa</city>
        <zip>31048</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Haifa</city>
        <zip>34362</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Holon</city>
        <zip>58100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jerusalem</city>
        <zip>91004</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jerusalem</city>
        <zip>91031</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jerusalem</city>
        <zip>91240</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kfar Saba</city>
        <zip>44281</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nahariya</city>
        <zip>22100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Poriya</city>
        <zip>15208</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Raanana</city>
        <zip>43000</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ramat-Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rehovot</city>
        <zip>76100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Safed</city>
        <zip>13110</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Catanzaro</city>
        <state>Calabria</state>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Napoli</city>
        <state>Campania</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bologna</city>
        <state>Emilia-Romagna</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Carpi</city>
        <state>Emilia-Romagna</state>
        <zip>41012</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ferrara</city>
        <state>Emilia-Romagna</state>
        <zip>44100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Parma</city>
        <state>Emilia-Romagna</state>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Palmanova</city>
        <state>Friuli-Venezia-Giulia</state>
        <zip>33057</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Daniele del Friuli</city>
        <state>Friuli-Venezia-Giulia</state>
        <zip>33038</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Udine</city>
        <state>Friuli-Venezia-Giulia</state>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00135</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00189</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bergamo</city>
        <state>Lombardia</state>
        <zip>24128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rozzano (Mi)</city>
        <state>Lombardia</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ascoli Piceno</city>
        <state>Marche</state>
        <zip>63100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Novara</city>
        <state>Piemonte</state>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sassari</city>
        <state>Sardegna</state>
        <zip>07100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pisa</city>
        <state>Toscana</state>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Treviso</city>
        <state>Veneto</state>
        <zip>31100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Legnano</city>
        <zip>20025</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sassuolo</city>
        <zip>41049</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chiba</city>
        <zip>270-2251</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>807-0051</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>811-0213</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>816-0864</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hokkaido</city>
        <zip>006-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hokkaido</city>
        <zip>063-0005</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hokkaido</city>
        <zip>065-0033</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hyogo</city>
        <zip>650-0047</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kanagawa</city>
        <zip>232-0024</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kanagawa</city>
        <zip>243-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kanagawa</city>
        <zip>247-8533</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kyoto</city>
        <zip>606-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nagasaki</city>
        <zip>856-8562</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oita</city>
        <zip>870-0263</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Okayama</city>
        <zip>700-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Osaka</city>
        <zip>565-8565</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Osaka</city>
        <zip>574-0074</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Osaka</city>
        <zip>580-0032</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saga</city>
        <zip>843-0393</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shizuoka</city>
        <zip>410-2295</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>101-8643</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>113-8431</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>160-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>196-0003</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dae-Gu</city>
        <zip>700-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Daejeon</city>
        <zip>301721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gangnam-gu, Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gwangju</city>
        <zip>501-757</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kangwon-do</city>
        <zip>220-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pusan</city>
        <zip>602-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>'s-Hertogenbosch</city>
        <zip>5223 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Amersfoort</city>
        <zip>3818 ES</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1061 AE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1091 AC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Apeldoorn</city>
        <zip>7334 DZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Blaricum</city>
        <zip>1261 AN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Den Haag</city>
        <zip>2597 AX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Deventer</city>
        <zip>7416 SE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dirksland</city>
        <zip>3247 BW</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Doetinchem</city>
        <zip>7009 BL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Drachten</city>
        <zip>9202 NN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Eindhoven</city>
        <zip>5623 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gorinchem</city>
        <zip>4204 AA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gouda</city>
        <zip>2803 HH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Groningen</city>
        <zip>9728 NT</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hardenberg</city>
        <zip>7772 SE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Harderwijk</city>
        <zip>3844 DG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Heerenveen</city>
        <zip>8441 PW</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Heerlen</city>
        <zip>6419 PC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Helmond</city>
        <zip>5707 HA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hilversum</city>
        <zip>1213 XZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hoofddorp</city>
        <zip>2134 TM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hoorn</city>
        <zip>1625 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nijmegen</city>
        <zip>6532 SZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>OSS</city>
        <zip>5342 BT</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Roermond</city>
        <zip>6043 CV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3045 PM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3083 AN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sittard-geleen</city>
        <zip>6162 BG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sneek</city>
        <zip>8601 ZR</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tiel</city>
        <zip>4002 WP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tilburg</city>
        <zip>5042AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Veldhoven</city>
        <zip>5504 DB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Venlo</city>
        <zip>5912 BL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Zoetermeer</city>
        <zip>2725 NA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Auckland</city>
        <zip>2025</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dunedin</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <zip>3204</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lower Hutt</city>
        <zip>6007</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New Plymouth</city>
        <zip>4310</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Palmerston North</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Takapuna, Auckland</city>
        <zip>0622</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tauranga</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Whangarei</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Miraflores, Lima</city>
        <state>Lima</state>
        <zip>Lima 18</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Martin de Porres</city>
        <state>Lima</state>
        <zip>Lima 31</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Callao</city>
        <zip>Callao 02</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lima Cercado</city>
        <zip>LIMA 01</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lima</city>
        <zip>Lima 11</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lima</city>
        <zip>Lima 27</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lima</city>
        <zip>Lima 33</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cebu City</city>
        <zip>6000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Davao</city>
        <zip>8000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manila</city>
        <zip>1000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Quezon City</city>
        <zip>1100</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Quezon City</city>
        <zip>1109</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Quezon City</city>
        <zip>1113</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bialystok</city>
        <zip>15-276</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-079</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bytom</city>
        <zip>41-902</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chrzanow</city>
        <zip>32-500</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gdansk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gdynia</city>
        <zip>81-423</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gdynia</city>
        <zip>81-472</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gdynia</city>
        <zip>81-519</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Inowroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Krakow</city>
        <zip>31-121</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Krakow</city>
        <zip>31-202</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lodz</city>
        <zip>91-347</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lubin</city>
        <zip>59-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mielec</city>
        <zip>39-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Olawa</city>
        <zip>55-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Opole</city>
        <zip>45-418</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Radom</city>
        <zip>26-617</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Skierniewice</city>
        <zip>96-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tarnow</city>
        <zip>33-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Torun</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tychy</city>
        <zip>43-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Walbrzych</city>
        <zip>58-309</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Warsaw</city>
        <zip>02-507</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <zip>00-685</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-637</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <zip>04-073</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wloclawek</city>
        <zip>87-800</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-349</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-367</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>51-124</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Zamosc</city>
        <zip>22-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Zielona Gora</city>
        <zip>65-046</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Baia Mare</city>
        <zip>430123</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Braila</city>
        <zip>810249</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brasov</city>
        <zip>500326</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <zip>011461</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <zip>011794</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <zip>014461</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <zip>022328</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <zip>041915</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <zip>050098</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400001</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Constanta</city>
        <zip>900591</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Craiova</city>
        <zip>200642</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Iasi</city>
        <zip>700503</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Targu Mures</city>
        <zip>540136</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barnaul</city>
        <zip>656024</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620039</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620109</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gatchina</city>
        <zip>188300</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kemerovo</city>
        <zip>650002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kemerovo</city>
        <zip>650036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Krasnoyarsk</city>
        <zip>660097</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>105187</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>111020</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>111539</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>117292</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>119620</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>119991</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>121 309</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>121552</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>127018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>127473</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nizhniy Novgorod</city>
        <zip>603035</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nizhniy Novgorod</city>
        <zip>603076</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630008</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630047</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Orenburg</city>
        <zip>460040</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Samara</city>
        <zip>443070</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saratov</city>
        <zip>410028</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saratov</city>
        <zip>410054</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St'Petersburg</city>
        <zip>194156</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St-Petersburg</city>
        <zip>193312</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St-Petersburg</city>
        <zip>195067</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St-Petersburg</city>
        <zip>199106</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>190000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>192242</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>193079</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>196247</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>196601</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>198013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>198205</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tomsk</city>
        <zip>643012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tyumen</city>
        <zip>625023</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tyumen</city>
        <zip>625026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <zip>813 69</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <zip>826 06</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <zip>833 05</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <zip>833 48</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kosice</city>
        <zip>040 22</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nitra</city>
        <zip>949 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nitra</city>
        <zip>950 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nove Zamky</city>
        <zip>940 52</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bloemfontein</city>
        <state>Free State</state>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Alberton</city>
        <state>Gauteng</state>
        <zip>1449</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2000</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0132</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Durban</city>
        <state>KwaZulu- Natal</state>
        <zip>4001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Durban</city>
        <state>KwaZulu- Natal</state>
        <zip>4052</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <state>Western Province</state>
        <zip>7500</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <state>Western Province</state>
        <zip>7530</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Panorama</city>
        <state>Western Province</state>
        <zip>7500</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Goodwood</city>
        <zip>7460</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kempton Park</city>
        <zip>1619</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paarl</city>
        <zip>7646</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Parktown West</city>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Parow</city>
        <zip>7505</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pretoria</city>
        <zip>0002</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pretoria</city>
        <zip>0041</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Somerset West</city>
        <zip>7130</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Worcester</city>
        <zip>6850</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lerida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Len</city>
        <zip>24071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oviedo</city>
        <zip>33006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Juan/Alicante</city>
        <zip>03550</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Sebastin de los Reyes/Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Sebastin</city>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vigo/Pontevedra</city>
        <zip>36200</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gteborg</city>
        <zip>SE-413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gteborg</city>
        <zip>SE-41685</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gteborg</city>
        <zip>SE-43180</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hssleholm</city>
        <zip>SE-28125</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jnkping</city>
        <zip>SE-551 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-11883</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vsters</city>
        <zip>SE-721 89</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>rebro</city>
        <zip>SE-70185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>stersund</city>
        <zip>SE-831 83</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kaohsiung City</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kaohsiung</city>
        <zip>833</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Taipei</city>
        <zip>111</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Taipei</city>
        <zip>220</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Yung Kang City</city>
        <zip>71044</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bangkoknoi</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chiangmai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Khon Kaen, Muang</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nakhon Ratchasima</city>
        <zip>30000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pathumthani</city>
        <zip>12120</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ankara</city>
        <zip>06500</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Erzurum</city>
        <zip>25240</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Eskisehir</city>
        <zip>26480</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Izmir</city>
        <zip>35340</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Izmir</city>
        <zip>35360</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49006</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Donetsk</city>
        <zip>83114</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kharkiv</city>
        <zip>61002</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kharkiv</city>
        <zip>61018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kharkiv</city>
        <zip>61039</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kharkiv</city>
        <zip>61176</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kyiv</city>
        <zip>01601</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kyiv</city>
        <zip>02091</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kyiv</city>
        <zip>02660</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kyiv</city>
        <zip>03049</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kyiv</city>
        <zip>03680</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kyiv</city>
        <zip>3115</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lugansk</city>
        <zip>91045</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lutsk</city>
        <zip>43024</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mykolaiv</city>
        <zip>54033</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Odesa</city>
        <zip>65014</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Simferopol</city>
        <zip>95026</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Exeter</city>
        <state>Devon</state>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Torquay</city>
        <state>Devon</state>
        <zip>TQ2 7AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Airdrie</city>
        <state>Lanarkshire</state>
        <zip>ML6 0JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Harrow</city>
        <state>Middlesex</state>
        <zip>HA1 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Northampton</city>
        <state>Northamptonshire</state>
        <zip>NN1 5BD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nottingham</city>
        <state>Nottinghamshire</state>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chertsey</city>
        <state>Surrey</state>
        <zip>KT16 0PZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Coventry</city>
        <state>West Midlands</state>
        <zip>CV2 2DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Antrim</city>
        <zip>BT41 2RL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chichester</city>
        <zip>PO19 6SE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>East Kilbride</city>
        <zip>G75 8RG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hertfordshire</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Liverpool</city>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paisley</city>
        <zip>PA2 9PN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stirling</city>
        <zip>FK8 2AU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>China</country>
    <country>Colombia</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Peru</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2009</study_first_submitted>
  <study_first_submitted_qc>October 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2009</study_first_posted>
  <results_first_submitted>June 9, 2017</results_first_submitted>
  <results_first_submitted_qc>July 12, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 10, 2017</results_first_posted>
  <disposition_first_submitted>September 11, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>September 11, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 22, 2014</disposition_first_posted>
  <last_update_submitted>July 12, 2017</last_update_submitted>
  <last_update_submitted_qc>July 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atherosclerosis</keyword>
  <keyword>Heart disease</keyword>
  <keyword>Cardiovascular disease</keyword>
  <keyword>Lp-PLA2 inhibitor</keyword>
  <keyword>The TIMI Study Group</keyword>
  <keyword>Coronary Heart Disease (CHD)</keyword>
  <keyword>Acute Coronary Syndrome (ACS)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darapladib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>480848/033</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>480848/033</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>480848/033</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>480848/033</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>480848/033</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>480848/033</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 868 centers in 36 countries: North America (282), Western Europe (210), Eastern Europe (166), Asia/Pacific (127), South America (83) during 07 December 2009 to 24 April 2014. A total of 13026 participants were randomized to the study.</recruitment_details>
      <pre_assignment_details>During the screening phase of the study, participants presenting with acute coronary syndrome (ACS) were randomized within 30 days. Approximately 77% of participants underwent percutaneous coronary intervention (PCI) for the qualifying event.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants were randomized to receive matching placebo once daily.</description>
        </group>
        <group group_id="P2">
          <title>Darapladib 160 mg</title>
          <description>Participants were randomized to receive darapladib 160 milligram (mg) enteric-coated tablets once daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6522"/>
                <participants group_id="P2" count="6504"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6347"/>
                <participants group_id="P2" count="6328"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="175"/>
                <participants group_id="P2" count="176"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="111"/>
                <participants group_id="P2" count="109"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study closed/terminated</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants were randomized to receive matching placebo once daily.</description>
        </group>
        <group group_id="B2">
          <title>Darapladib 160 mg</title>
          <description>Participants were randomized to receive darapladib 160 mg enteric-coated tablets once daily.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6522"/>
            <count group_id="B2" value="6504"/>
            <count group_id="B3" value="13026"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.3" spread="9.50"/>
                    <measurement group_id="B2" value="64.1" spread="9.52"/>
                    <measurement group_id="B3" value="64.2" spread="9.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1669"/>
                    <measurement group_id="B2" value="1657"/>
                    <measurement group_id="B3" value="3326"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4853"/>
                    <measurement group_id="B2" value="4847"/>
                    <measurement group_id="B3" value="9700"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White - White/Caucasian/European Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5329"/>
                    <measurement group_id="B2" value="5331"/>
                    <measurement group_id="B3" value="10660"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian - East Asian Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="351"/>
                    <measurement group_id="B2" value="349"/>
                    <measurement group_id="B3" value="700"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian - Central/South Asian Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="200"/>
                    <measurement group_id="B2" value="211"/>
                    <measurement group_id="B3" value="411"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American/African Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="160"/>
                    <measurement group_id="B2" value="155"/>
                    <measurement group_id="B3" value="315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White - Arabic/North African Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="138"/>
                    <measurement group_id="B2" value="119"/>
                    <measurement group_id="B3" value="257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian - South East Asian Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="123"/>
                    <measurement group_id="B2" value="116"/>
                    <measurement group_id="B3" value="239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian - Japanese Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mixed Race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian - Mixed Race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White - Mixed Race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With First Occurrence of Any Event in the Composite of Major Coronary Events During the Time Period for Follow-up (FU) of Cardiovascular (CV) Event</title>
        <description>Coronary heart disease (CHD) death=occurrence of a fatal myocardial infarction (MI), death caused by documented cardiac arrest, death resulting from heart failure in a participant with known CHD, death from other forms of acute/chronic CHD, unwitnessed death of unknown origin, or sudden death. Acute MI=evidence of myocardial necrosis in a clinical setting consistent with myocardial ischemia. Prior MI diagnosed post-randomization (e.g., silent MI)=the development of new pathological Q waves with/without symptoms OR imaging evidence of a region of loss of viable myocardium that is thinned and fails to contract, in the absence of a nonischemic cause (pre-event imaging data required for verification of new abnormality), OR pathological findings of a healed/healing MI. Urgent coronary revascularization (CR) for MI=ischemic discomfort at rest that prompted CR during the same hospitalization or resulted in hospital transfer for the purpose of CR.</description>
        <time_frame>From randomization until the End-of-Treatment visit or the last date on which endpoints were able to be assessed (up to 3.80 years)</time_frame>
        <population>All-Randomized intent-to-treat (ITT) Population consisted of all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were randomized to receive matching placebo once daily.</description>
          </group>
          <group group_id="O2">
            <title>Darapladib 160 mg</title>
            <description>Participants were randomized to receive darapladib 160 mg enteric-coated tablets once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With First Occurrence of Any Event in the Composite of Major Coronary Events During the Time Period for Follow-up (FU) of Cardiovascular (CV) Event</title>
          <description>Coronary heart disease (CHD) death=occurrence of a fatal myocardial infarction (MI), death caused by documented cardiac arrest, death resulting from heart failure in a participant with known CHD, death from other forms of acute/chronic CHD, unwitnessed death of unknown origin, or sudden death. Acute MI=evidence of myocardial necrosis in a clinical setting consistent with myocardial ischemia. Prior MI diagnosed post-randomization (e.g., silent MI)=the development of new pathological Q waves with/without symptoms OR imaging evidence of a region of loss of viable myocardium that is thinned and fails to contract, in the absence of a nonischemic cause (pre-event imaging data required for verification of new abnormality), OR pathological findings of a healed/healing MI. Urgent coronary revascularization (CR) for MI=ischemic discomfort at rest that prompted CR during the same hospitalization or resulted in hospital transfer for the purpose of CR.</description>
          <population>All-Randomized intent-to-treat (ITT) Population consisted of all randomized participants.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6522"/>
                <count group_id="O2" value="6504"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="910"/>
                    <measurement group_id="O2" value="903"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.929</p_value>
            <p_value_desc>Statistical significance of this p-value is based on the alpha-spending function of this study.</p_value_desc>
            <method>Cox Proportional Hazard Regression Model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95.02</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With First Occurrence of Any Component of the Composite of Major Adverse Cardiovascular Events (Cardiovascular [CV] Death, Non-fatal MI or Non-fatal Stroke) During the Time Period for Follow-up of CV Events</title>
        <description>CV death=death due to a CV cause, which included but was not limited to deaths resulting from stroke, arrhythmia, sudden death (witnessed/unwitnessed), MI, heart failure, pulmonary embolism, peripheral arterial disease, or complications of a CV procedure. Deaths not clearly attributable to non-CV causes are considered to be CV deaths. Acute MI=evidence of myocardial necrosis in a clinical setting consistent with myocardial ischemia. Prior MI diagnosed post-randomization (e.g., silent MI)=the development of new pathological Q waves with/without symptoms OR imaging evidence of a region of loss of viable myocardium that is thinned and fails to contract, in the absence of a non-ischemic cause (pre-event imaging data required for verification of new abnormality), OR pathological findings of a healed/healing MI. Stroke=presence of a new focal neurologic deficit thought to be of vascular origin, with signs/symptoms lasting &gt;24 hours or results in death (in &lt;24 hours).</description>
        <time_frame>From randomization until the End-of-Treatment visit or the last date on which endpoints were able to be assessed (up to 3.80 years)</time_frame>
        <population>All-Randomized ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were randomized to receive matching placebo once daily.</description>
          </group>
          <group group_id="O2">
            <title>Darapladib 160 mg</title>
            <description>Participants were randomized to receive darapladib 160 mg enteric-coated tablets once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With First Occurrence of Any Component of the Composite of Major Adverse Cardiovascular Events (Cardiovascular [CV] Death, Non-fatal MI or Non-fatal Stroke) During the Time Period for Follow-up of CV Events</title>
          <description>CV death=death due to a CV cause, which included but was not limited to deaths resulting from stroke, arrhythmia, sudden death (witnessed/unwitnessed), MI, heart failure, pulmonary embolism, peripheral arterial disease, or complications of a CV procedure. Deaths not clearly attributable to non-CV causes are considered to be CV deaths. Acute MI=evidence of myocardial necrosis in a clinical setting consistent with myocardial ischemia. Prior MI diagnosed post-randomization (e.g., silent MI)=the development of new pathological Q waves with/without symptoms OR imaging evidence of a region of loss of viable myocardium that is thinned and fails to contract, in the absence of a non-ischemic cause (pre-event imaging data required for verification of new abnormality), OR pathological findings of a healed/healing MI. Stroke=presence of a new focal neurologic deficit thought to be of vascular origin, with signs/symptoms lasting &gt;24 hours or results in death (in &lt;24 hours).</description>
          <population>All-Randomized ITT Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6522"/>
                <count group_id="O2" value="6504"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="838"/>
                    <measurement group_id="O2" value="824"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.777</p_value>
            <p_value_desc>Statistical significance of this p-value is based on the alpha-spending function of this study.</p_value_desc>
            <method>Cox Proportional Hazard Regression Model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95.02</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cardiovascular Death During the Time Period for Follow-up of Cardiovascular Events</title>
        <description>CV death is defined as a death due to a CV cause, which includes but is not limited to deaths resulting from stroke, arrhythmia, sudden death (witnessed/unwitnessed), MI, heart failure, pulmonary embolism, peripheral arterial disease, or complications of a CV procedure. Deaths not clearly attributable to non-CV causes are considered to be CV deaths.</description>
        <time_frame>From randomization until the End-of-Treatment visit or the last date on which endpoints were able to be assessed (up to 3.80 years)</time_frame>
        <population>All-Randomized ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Darapladib 160 mg</title>
            <description>Participants were randomized to receive matching placebo once daily.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants were randomized to receive darapladib 160 mg enteric-coated tablets once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cardiovascular Death During the Time Period for Follow-up of Cardiovascular Events</title>
          <description>CV death is defined as a death due to a CV cause, which includes but is not limited to deaths resulting from stroke, arrhythmia, sudden death (witnessed/unwitnessed), MI, heart failure, pulmonary embolism, peripheral arterial disease, or complications of a CV procedure. Deaths not clearly attributable to non-CV causes are considered to be CV deaths.</description>
          <population>All-Randomized ITT Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6522"/>
                <count group_id="O2" value="6504"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="268"/>
                    <measurement group_id="O2" value="243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.274</p_value>
            <p_value_desc>Statistical significance of this p-value is based on the alpha-spending function of this study.</p_value_desc>
            <method>Cox Proportional Hazard Regression Model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With First Occurrence of MI (Fatal/Nonfatal) During the Time Period for Follow-up of Cardiovascular Events</title>
        <description>Acute MI is defined as evidence of myocardial necrosis in a clinical setting consistent with myocardial ischemia. Prior MI diagnosed post-randomization (e.g., silent MI)=the development of new pathological Q waves with/without symptoms OR imaging evidence of a region of loss of viable myocardium that is thinned and fails to contract, in the absence of a non-ischemic cause (pre-event imaging data required for verification of new abnormality), OR pathological findings of a healed/healing MI.</description>
        <time_frame>From randomization until the End-of-Treatment visit or the last date on which endpoints were able to be assessed (up to 3.80 years)</time_frame>
        <population>All-Randomized ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were randomized to receive matching placebo once daily.</description>
          </group>
          <group group_id="O2">
            <title>Darapladib 160 mg</title>
            <description>Participants were randomized to receive darapladib 160 mg enteric-coated tablets once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With First Occurrence of MI (Fatal/Nonfatal) During the Time Period for Follow-up of Cardiovascular Events</title>
          <description>Acute MI is defined as evidence of myocardial necrosis in a clinical setting consistent with myocardial ischemia. Prior MI diagnosed post-randomization (e.g., silent MI)=the development of new pathological Q waves with/without symptoms OR imaging evidence of a region of loss of viable myocardium that is thinned and fails to contract, in the absence of a non-ischemic cause (pre-event imaging data required for verification of new abnormality), OR pathological findings of a healed/healing MI.</description>
          <population>All-Randomized ITT Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6522"/>
                <count group_id="O2" value="6504"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="564"/>
                    <measurement group_id="O2" value="547"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.631</p_value>
            <method>Cox Proportional Hazard Regression Model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
            <estimate_desc>A hazard ratio &lt;1 indicates a lower risk with this treatment compared to Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With First Occurrence of Stroke (Fatal/Non-fatal) During the Time Period for Follow-up of Cardiovascular Events</title>
        <description>Stroke is defined as the presence of a new focal neurologic deficit thought to be of vascular origin, with signs/symptoms lasting &gt;24 hours or results in death (in &lt;24 hours).</description>
        <time_frame>From randomization until the End-of-Treatment visit or the last date on which endpoints were able to be assessed (up to 3.80 years)</time_frame>
        <population>All-Randomized ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were randomized to receive matching placebo once daily.</description>
          </group>
          <group group_id="O2">
            <title>Darapladib 160 mg</title>
            <description>Participants were randomized to receive darapladib 160 mg enteric-coated tablets once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With First Occurrence of Stroke (Fatal/Non-fatal) During the Time Period for Follow-up of Cardiovascular Events</title>
          <description>Stroke is defined as the presence of a new focal neurologic deficit thought to be of vascular origin, with signs/symptoms lasting &gt;24 hours or results in death (in &lt;24 hours).</description>
          <population>All-Randomized ITT Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6522"/>
                <count group_id="O2" value="6504"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130"/>
                    <measurement group_id="O2" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.354</p_value>
            <method>Cox Proportional Hazard Regression Model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.42</ci_upper_limit>
            <estimate_desc>A hazard ratio &lt; 1 indicates a lower risk with this treatment compared to Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With CHD Death During the Time Period for Follow-up of Cardiovascular Events</title>
        <description>CHD death is defined as the occurrence of a fatal MI, death caused by documented cardiac arrest, death resulting from heart failure in a participant with known CHD, death from other forms of acute/chronic CHD, unwitnessed death of unknown origin, or sudden death.</description>
        <time_frame>From randomization until the End-of-Treatment visit or the last date on which endpoints were able to be assessed (up to 3.80 years)</time_frame>
        <population>All-Randomized ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were randomized to receive matching placebo once daily.</description>
          </group>
          <group group_id="O2">
            <title>Darapladib 160 mg</title>
            <description>Participants were randomized to receive darapladib 160 mg enteric-coated tablets once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With CHD Death During the Time Period for Follow-up of Cardiovascular Events</title>
          <description>CHD death is defined as the occurrence of a fatal MI, death caused by documented cardiac arrest, death resulting from heart failure in a participant with known CHD, death from other forms of acute/chronic CHD, unwitnessed death of unknown origin, or sudden death.</description>
          <population>All-Randomized ITT Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6522"/>
                <count group_id="O2" value="6504"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="241"/>
                    <measurement group_id="O2" value="211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.161</p_value>
            <method>Cox Proportional Hazard Regression Model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Urgent Coronary Revascularization for Myocardial Ischemia During the Time Period for Follow-up of Cardiovascular Events</title>
        <description>Urgent coronary revascularization for myocardial ischemia is defined as ischemic discomfort at rest that prompts coronary revascularization (PCI or coronary artery bypass graft [CABG]) during the same hospitalization or resulting in hospital transfer for the purpose of coronary revascularization. PCI is defined as any attempt at revascularization even if not successful (e.g., angioplasty, atherectomy or stenting).</description>
        <time_frame>From randomization until the End-of-Treatment visit or the last date on which endpoints were able to be assessed (up to 3.80 years)</time_frame>
        <population>All-Randomized ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were randomized to receive matching placebo once daily.</description>
          </group>
          <group group_id="O2">
            <title>Darapladib 160 mg</title>
            <description>Participants were randomized to receive darapladib 160 mg enteric-coated tablets once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Urgent Coronary Revascularization for Myocardial Ischemia During the Time Period for Follow-up of Cardiovascular Events</title>
          <description>Urgent coronary revascularization for myocardial ischemia is defined as ischemic discomfort at rest that prompts coronary revascularization (PCI or coronary artery bypass graft [CABG]) during the same hospitalization or resulting in hospital transfer for the purpose of coronary revascularization. PCI is defined as any attempt at revascularization even if not successful (e.g., angioplasty, atherectomy or stenting).</description>
          <population>All-Randomized ITT Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6522"/>
                <count group_id="O2" value="6504"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218"/>
                    <measurement group_id="O2" value="237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.360</p_value>
            <method>Cox Proportional Hazard Regression Model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With First Occurrence of Any Event in the Composite of Total Coronary Events (CHD Death, Non-fatal MI, Hospitalization for Unstable Angina, or Any Coronary Revascularization Procedure) During the Time Period for FU of CV Events</title>
        <description>CHD death, acute MI, and prior MI diagnosed post-randomization are defined in the primary endpoint (major coronary events). Hospitalization for unstable angina=one of the following, but not fulfilling the criteria for MI: ischemic discomfort at rest associated with electrocardiogram (ECG) changes leading to hospitalization; ischemic discomfort at rest regardless of ECG changes leading to hospitalization and revascularization during the same admission; ischemic discomfort at rest in hospital associated with ECG changes; ischemic discomfort at rest in hospital without ECG changes resulting in revascularization during the same admission. NOTE: The event was not considered to be unstable angina if, after invasive/non-invasive testing or other diagnostic testing, the discomfort was found not to be caused by myocardial ischemia. Coronary revascularization procedures exclude PCI planned prior to randomization but performed after randomization.</description>
        <time_frame>From randomization until the End-of-Treatment visit or the last date on which endpoints were able to be assessed (up to 3.80 years)</time_frame>
        <population>All-Randomized ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were randomized to receive matching placebo once daily.</description>
          </group>
          <group group_id="O2">
            <title>Darapladib 160 mg</title>
            <description>Participants were randomized to receive darapladib 160 mg enteric-coated tablets once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With First Occurrence of Any Event in the Composite of Total Coronary Events (CHD Death, Non-fatal MI, Hospitalization for Unstable Angina, or Any Coronary Revascularization Procedure) During the Time Period for FU of CV Events</title>
          <description>CHD death, acute MI, and prior MI diagnosed post-randomization are defined in the primary endpoint (major coronary events). Hospitalization for unstable angina=one of the following, but not fulfilling the criteria for MI: ischemic discomfort at rest associated with electrocardiogram (ECG) changes leading to hospitalization; ischemic discomfort at rest regardless of ECG changes leading to hospitalization and revascularization during the same admission; ischemic discomfort at rest in hospital associated with ECG changes; ischemic discomfort at rest in hospital without ECG changes resulting in revascularization during the same admission. NOTE: The event was not considered to be unstable angina if, after invasive/non-invasive testing or other diagnostic testing, the discomfort was found not to be caused by myocardial ischemia. Coronary revascularization procedures exclude PCI planned prior to randomization but performed after randomization.</description>
          <population>All-Randomized ITT Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6522"/>
                <count group_id="O2" value="6504"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1352"/>
                    <measurement group_id="O2" value="1290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.202</p_value>
            <method>Cox Proportional Hazard Regression Model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
            <estimate_desc>A hazard ratio &lt;1 indicates a lower risk with this treatment compared to Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With First Occurrence of Any Coronary Revascularization Procedures (Excluding Coronary Revascularization Planned Prior to Randomization, But Performed After Randomization) During the Time Period for Follow-up of Cardiovascular Event</title>
        <description>All coronary revascularization procedures (except for PCI planned prior to randomization but performed after randomization) are included. Examples include coronary artery bypass graft, balloon angioplasty and stenting. The number of participants, with first occurrence of any coronary revascularization procedures, were reported.</description>
        <time_frame>From randomization until the End-of-Treatment visit or the last date on which endpoints were able to be assessed (up to 3.80 years)</time_frame>
        <population>All-Randomized ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were randomized to receive matching placebo once daily.</description>
          </group>
          <group group_id="O2">
            <title>Darapladib 160 mg</title>
            <description>Participants were randomized to receive darapladib 160 mg enteric-coated tablets once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With First Occurrence of Any Coronary Revascularization Procedures (Excluding Coronary Revascularization Planned Prior to Randomization, But Performed After Randomization) During the Time Period for Follow-up of Cardiovascular Event</title>
          <description>All coronary revascularization procedures (except for PCI planned prior to randomization but performed after randomization) are included. Examples include coronary artery bypass graft, balloon angioplasty and stenting. The number of participants, with first occurrence of any coronary revascularization procedures, were reported.</description>
          <population>All-Randomized ITT Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6522"/>
                <count group_id="O2" value="6504"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="967"/>
                    <measurement group_id="O2" value="926"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.329</p_value>
            <method>Cox Proportional Hazard Regression Model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With First Occurrence of Any Component of the Composite of All-cause Mortality, Non-fatal MI, or Nonfatal Stroke During the Time Period for Follow-up of Cardiovascular Events</title>
        <description>Acute MI is defined as evidence of myocardial necrosis in a clinical setting consistent with myocardial ischemia. Prior MI diagnosed post-randomization (e.g., silent MI)=the development of new pathological Q waves with/without symptoms OR imaging evidence of a region of loss of viable myocardium that is thinned and fails to contract, in the absence of a non-ischemic cause (pre-event imaging data required for verification of new abnormality), OR pathological findings of a healed/healing MI. Stroke=presence of a new focal neurologic deficit thought to be of vascular origin, with signs/symptoms lasting &gt;24 hours or results in death (in &lt;24 hours).</description>
        <time_frame>From randomization until the End-of-Treatment visit or the last date on which endpoints were able to be assessed (up to 3.80 years)</time_frame>
        <population>All-Randomized ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were randomized to receive matching placebo once daily.</description>
          </group>
          <group group_id="O2">
            <title>Darapladib 160 mg</title>
            <description>Participants were randomized to receive darapladib 160 mg enteric-coated tablets once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With First Occurrence of Any Component of the Composite of All-cause Mortality, Non-fatal MI, or Nonfatal Stroke During the Time Period for Follow-up of Cardiovascular Events</title>
          <description>Acute MI is defined as evidence of myocardial necrosis in a clinical setting consistent with myocardial ischemia. Prior MI diagnosed post-randomization (e.g., silent MI)=the development of new pathological Q waves with/without symptoms OR imaging evidence of a region of loss of viable myocardium that is thinned and fails to contract, in the absence of a non-ischemic cause (pre-event imaging data required for verification of new abnormality), OR pathological findings of a healed/healing MI. Stroke=presence of a new focal neurologic deficit thought to be of vascular origin, with signs/symptoms lasting &gt;24 hours or results in death (in &lt;24 hours).</description>
          <population>All-Randomized ITT Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6522"/>
                <count group_id="O2" value="6504"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="928"/>
                    <measurement group_id="O2" value="914"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.797</p_value>
            <method>Cox Proportional Hazard Regression Model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With First Occurrence of Any Event in the Composite of CHD Death and Non-fatal MI During the Time Period for Follow-up of Cardiovascular Events</title>
        <description>Acute MI is defined as evidence of myocardial necrosis in a clinical setting consistent with myocardial ischemia. Prior MI diagnosed post-randomization (e.g., silent MI)=the development of new pathological Q waves with/without symptoms OR imaging evidence of a region of loss of viable myocardium that is thinned and fails to contract, in the absence of a non-ischemic cause (pre-event imaging data required for verification of new abnormality), OR pathological findings of a healed/healing MI. CHD death is defined as the occurrence of a fatal MI, death caused by documented cardiac arrest, death resulting from heart failure in a participant with known CHD, death from other forms of acute/chronic CHD, unwitnessed death of unknown origin, or sudden death.</description>
        <time_frame>From randomization until the End-of-Treatment visit or the last date on which endpoints were able to be assessed (up to 3.80 years)</time_frame>
        <population>All-Randomized ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were randomized to receive matching placebo once daily.</description>
          </group>
          <group group_id="O2">
            <title>Darapladib 160 mg</title>
            <description>Participants were randomized to receive darapladib 160 mg enteric-coated tablets once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With First Occurrence of Any Event in the Composite of CHD Death and Non-fatal MI During the Time Period for Follow-up of Cardiovascular Events</title>
          <description>Acute MI is defined as evidence of myocardial necrosis in a clinical setting consistent with myocardial ischemia. Prior MI diagnosed post-randomization (e.g., silent MI)=the development of new pathological Q waves with/without symptoms OR imaging evidence of a region of loss of viable myocardium that is thinned and fails to contract, in the absence of a non-ischemic cause (pre-event imaging data required for verification of new abnormality), OR pathological findings of a healed/healing MI. CHD death is defined as the occurrence of a fatal MI, death caused by documented cardiac arrest, death resulting from heart failure in a participant with known CHD, death from other forms of acute/chronic CHD, unwitnessed death of unknown origin, or sudden death.</description>
          <population>All-Randomized ITT Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6522"/>
                <count group_id="O2" value="6504"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="725"/>
                    <measurement group_id="O2" value="701"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.546</p_value>
            <method>Cox Proportional Hazard Regression Model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
            <estimate_desc>A hazard ratio &lt;1 indicates a lower risk with this treatment compared to Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All-cause Mortality During the Time Period for Vital Status</title>
        <description>Number of participants who died, during the vital status time-period were reported. The participants who were known to have died, date of death was used; for participants who completed the study the study completion date was used; for participants who withdrew from the study where vital status was ascertained , and are known to have not died , the last known date to be alive was used and for participants whom vital status was not ascertained, following study withdrawal the study withdrawal date was used.</description>
        <time_frame>From randomization until the End-of-Treatment visit or the last date on which endpoints were able to be assessed (up to 3.80 years)</time_frame>
        <population>All-Randomized ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were randomized to receive matching placebo once daily.</description>
          </group>
          <group group_id="O2">
            <title>Darapladib 160 mg</title>
            <description>Participants were randomized to receive darapladib 160 mg enteric-coated tablets once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All-cause Mortality During the Time Period for Vital Status</title>
          <description>Number of participants who died, during the vital status time-period were reported. The participants who were known to have died, date of death was used; for participants who completed the study the study completion date was used; for participants who withdrew from the study where vital status was ascertained , and are known to have not died , the last known date to be alive was used and for participants whom vital status was not ascertained, following study withdrawal the study withdrawal date was used.</description>
          <population>All-Randomized ITT Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6522"/>
                <count group_id="O2" value="6504"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="403"/>
                    <measurement group_id="O2" value="376"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.362</p_value>
            <method>Cox Proportional Hazard Regression Model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>SAEs and non-serious AEs were collected from start of the study treatment up to 42 days after last dose of study treatment/FU visit.</time_frame>
      <desc>SAEs and non-serious AEs were collected in members of the Safety Population, comprised of all randomized participants who received at least one dose of investigational product. Post-randomization AEs have an onset date that is on or after the randomization date. The safety population excluded 57 participants in the placebo group and 52 participants in the darapladib group who were randomized but did not receive study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants were randomized to receive matching placebo once daily.</description>
        </group>
        <group group_id="E2">
          <title>Darapladib 160 mg</title>
          <description>Participants were randomized to receive darapladib 160 mg enteric-coated tablets once daily.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="403" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="376" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3011" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2933" subjects_at_risk="6452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Agranulocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Anaemia macrocytic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Aplastic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Heparin-induced thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hypercoagulation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy mediastinal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Lymphoid tissue hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Microcytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Normochromic normocytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Splenic infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cerebellar haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Acute left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="446" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="432" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="272" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="266" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="546" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="562" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Arrhythmia supraventricular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Arteriospasm coronary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="108" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Atrial thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Bradyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Bundle branch block left</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cardiac aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cardiac asthma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cardiac discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="176" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="170" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="101" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="107" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cardiorenal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cardiovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cardiovascular insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Chronotropic incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Conduction disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="145" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="139" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Coronary artery dissection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Coronary artery insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Coronary artery perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Coronary artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Dilatation ventricular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hypertensive heart disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Interventricular septum rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Intracardiac thrombus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Microvascular coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Mitral valve disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Myocardial fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Myocardial rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Myopericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Nodal rhythm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Paroxysmal arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pericardial haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pleuropericarditis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Postinfarction angina</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Prinzmetal angina</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pulseless electrical activity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Restrictive cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Sinoatrial block</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Sinus arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Stress cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Supraventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Supraventricular tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Tachycardia paroxysmal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Torsade de pointes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Trifascicular block</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Ventricle rupture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Ventricular dyssynchrony</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Ventricular tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="6452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial septal defect</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Gastrointestinal arteriovenous malformation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Odontogenic cyst</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Phimosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Deafness neurosensory</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Ear haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hearing impaired</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Sudden hearing loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Vestibular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Autoimmune thyroiditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Primary hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Accommodation disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Age-related macular degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Amaurosis fugax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Blindness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Blindness unilateral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cataract nuclear</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Eye haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Eyelid cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Lens dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Macular hole</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Open angle glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Optic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Retinal artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Retinoschisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal adhesions</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Abdominal strangulated hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Abdominal wall haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Abnormal faeces</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Alcoholic pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Barretts oesophagus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Brunners gland hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Caecitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Coeliac artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Colonic pseudo-obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Crohns disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Diabetic gastroparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Diaphragmatic hernia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Duodenal polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Duodenogastric reflux</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Enterocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Enterovesical fistula</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Erosive oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Faeces discoloured</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Femoral hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Gastric disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Gastric perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Gastric polyps</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Gastritis atrophic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Gastritis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Gastroduodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Gastroduodenitis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Gastrointestinal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Gastrooesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Haemorrhagic erosive gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hyperchlorhydria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Ileal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Ileal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Inguinal hernia, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Intestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Intestinal infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Intestinal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Intra-abdominal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Large intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Large intestinal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Mallory-Weiss syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Megacolon</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Mesenteric artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Mesenteric vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Obstruction gastric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Oesophageal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Oesophageal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pancreatic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pancreatic pseudocyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pancreatitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pancreatitis relapsing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Peptic ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Peptic ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Periproctitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Peritoneal adhesions</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Peritoneal mesothelial hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pneumoperitoneum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Radicular cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Rectal fissure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Rectal polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Rectal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Reflux gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Short-bowel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Small intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Small intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Umbilical hernia, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Uraemic gastropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Varices oesophageal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Device malfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Device occlusion</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Drug withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hernia obstructive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hypothermia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Local swelling</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Medical device complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Mucosal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Nodule</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="298" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="248" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Patient-device incompatibility</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pelvic mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Polyserositis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pseudopolyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Puncture site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Stent malfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Stent-graft endoleak</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Surgical failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Thrombosis in device</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Vessel puncture site thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Alcoholic liver disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Autoimmune hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Bile duct stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Biliary dyskinesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cholangitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hepatic cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hepatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hepatitis alcoholic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hepatitis cholestatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hepatitis toxic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hepatocellular injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hepatorenal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Ischaemic hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Liver injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Anaphylactic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Sarcoidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Abscess intestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Acarodermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Acute tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Appendiceal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Bacterial prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Bone abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Burkholderia pseudomallei infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Bursitis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Campylobacter infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cellulitis staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cholangitis suppurative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Creutzfeldt-Jakob disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Device related sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Diabetic foot infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Diabetic gangrene</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Eczema infected</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Endocarditis enterococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Enteritis infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Gallbladder abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Gallbladder empyema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Gastric infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Gastroenteritis clostridial</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Gastroenteritis norovirus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Graft infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Groin infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Haematoma infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Helicobacter infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hepatitis C</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hepatitis E</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hepatitis infectious mononucleosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Infected dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Infected lymphocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Klebsiella infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Klebsiella sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Labyrinthitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Lymphangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Mastoiditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Mediastinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Meningitis tuberculous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Necrotising fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Neuroborreliosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Osteomyelitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Osteomyelitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pelvic abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pericarditis tuberculous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Peritoneal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pneumococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="113" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="130" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pneumonia fungal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pneumonia influenzal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pneumonia pseudomonas aeruginosa</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pneumonia staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pneumonia streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Post procedural pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Post procedural sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Postoperative abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pseudomembranous colitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pseudomonas infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pulmonary sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pyoderma streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Renal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Salmonellosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Scrotal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Skin bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Staphylococcal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Staphylococcal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Streptococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Streptococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Superinfection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Testicular abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Urinary tract infection enterococcal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Urinary tract infection pseudomonal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Wound infection pseudomonas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Wound infection staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Wound sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pneumonia legionella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Afferent loop syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Anaemia postoperative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Anastomotic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Arterial restenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Burns second degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Burns third degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cardiac function disturbance postoperative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cardiac procedure complication</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Carotid artery restenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cerebral hyperperfusion syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Chest injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Comminuted fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Contrast media reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Coronary artery reocclusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Coronary artery restenosis</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cystitis radiation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Dural tear</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Electric shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Exposure via inhalation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Eye penetration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Fat embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Foreign body</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Fractured ischium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder postoperative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Gastrointestinal injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Graft thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Gun shot wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Heart injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Heat exhaustion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Heat stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Incision site pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Intestinal anastomosis complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Kidney contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Mountain sickness acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Peroneal nerve injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pneumoconiosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Post procedural contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Post procedural fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Post procedural myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Post-traumatic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Postoperative ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Postoperative wound complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Postpericardiotomy syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Procedural headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pseudomeningocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pubis fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pulmonary contusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Renal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Scapula fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Scrotal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Shunt stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Shunt thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Skull fractured base</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Spinal column injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Splenic injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Sternal fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Subcutaneous haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Tendon injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Traumatic intracranial haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Traumatic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Traumatic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Vascular graft complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Vascular graft occlusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Vascular graft thrombosis0</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Vascular procedure complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Wound necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Ammonia increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cardiac enzymes increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cardiac output decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cardiac stress test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Clostridium test positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>ECG signs of myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Ejection fraction decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Electrocardiogram ST segment depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Electrocardiogram ST segment elevation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Exercise test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Fibrin D dimer increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Laboratory test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Platelet count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pulmonary function test decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Troponin I increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Troponin T increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hydraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hypophagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Insulin-requiring type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Abdominal wall abscess</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ankylosing spondylitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Compartment syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Fracture malunion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Fracture nonunion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Gouty arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Joint instability</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Limb discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Muscle disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Muscle haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Osteochondritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Plantar fascial fibromatosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Polyarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Polymyalgia rheumatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Polymyositis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Psoriatic arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Sensation of heaviness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Sjogrens syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Spondyloarthropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Spondylolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Sympathetic posterior cervical syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Acute promyelocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma gastric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma pancreas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Adenoma benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Adenosquamous cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Anal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Angiocentric lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Angiosarcoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma recurrent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Benign anorectal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Benign breast neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Benign gastric neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Benign gastrointestinal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Benign laryngeal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Benign lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Benign neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of adrenal gland</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of prostate</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Bile duct cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Bladder cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Bladder cancer stage 0, with cancer in situ</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Bladder papilloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Bone giant cell tumour benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Borderline ovarian tumour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Brain neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Breast cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Central nervous system neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cerebellar tumour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cholangiocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Choroid melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Chronic myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Clear cell renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Colorectal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cystadenocarcinoma ovary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Desmoplastic melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Diffuse large B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Essential thrombocythaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Fibroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Gastric cancer stage I</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Gastric neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Gastrointestinal cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Gastrointestinal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stromal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stromal tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Gastrointestinal tract adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Glioblastoma multiforme</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Glottis carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Haemangioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Haemangioma of liver</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hepatic cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hepatocellular carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Large cell lung cancer stage IV</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Large intestine benign neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Laryngeal squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Leiomyosarcoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Lip neoplasm malignant stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Lip squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Lung carcinoma cell type unspecified recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Lung squamous cell carcinoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Lung squamous cell carcinoma stage I</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm of ampulla of Vater</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm of unknown primary site</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Melanoma recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Meningioma benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Mesothelioma malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Metastases to lymph nodes</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Metastases to peritoneum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Metastases to pleura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Metastases to spine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Metastatic bronchial carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Metastatic gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Metastatic lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Metastatic malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Metastatic renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Metastatic squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Metastatic uterine cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Myeloproliferative disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Neurilemmoma benign</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Neuroendocrine carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Neuroendocrine carcinoma of the skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Neuroendocrine tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer stage IIIB</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Oesophageal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Oesophageal cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Oral cavity cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Oropharyngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Osteosarcoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Ovarian cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Ovarian germ cell teratoma benign</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Paraneoplastic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Paraproteinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Plasmacytoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pleomorphic adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Polycythaemia vera</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Precursor B-lymphoblastic lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Prostate cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Prostate cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Prostatic adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Rectal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Rectal cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Rectosigmoid cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Renal cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma stage II</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Renal oncocytoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Sarcoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Signet-ring cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Skin cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Small intestine adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of lung</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the tongue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>T-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Testis cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Thymoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Thyroid cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Tongue cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Tongue carcinoma stage IV</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Tongue neoplasm malignant stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Tonsil cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Tracheal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Vaginal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Allergy to arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Basilar migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Brain injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Brain stem stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Carotid arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Carotid artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Carotid artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Carotid sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cerebellar ataxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cerebellar infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cerebral arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cerebral artery embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cerebral circulatory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cerebrovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cerebrovascular insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cervical myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cervical neuritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cervical radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Complex regional pain syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Dementia Alzheimers type</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Dysaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Embolic stroke</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Frontotemporal dementia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Haemorrhagic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Haemorrhagic transformation stroke</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Head discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hemiplegia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hemiplegic migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hyperaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic coma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hypotonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hypoxic-ischaemic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Intercostal neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Intracranial haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Ischaemic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="93" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Monoparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Monoplegia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Motor neurone disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis relapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Narcolepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Neuroglycopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Normal pressure hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Occipital neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Paraplegia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Paresis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Parkinsons disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Postictal paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Sensory disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Simple partial seizures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Speech disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Spinal epidural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Spondylitic myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Status epilepticus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Thalamic infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Transient global amnesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Trigeminal neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>VIIth nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Vascular encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Vertebral artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Vertigo CNS origin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Ectropion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cerebellar haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal behaviour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Affective disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Alcohol abuse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Alcohol withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Anxiety disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Bipolar I disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Depression suicidal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Drug abuse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Emotional distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Mental disorder due to a general medical condition</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Mood disorder due to a general medical condition</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Psychotic disorder due to a general medical condition</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Schizophrenia, undifferentiated type</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Substance abuse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute prerenal failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Bladder outlet obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Bladder stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Calculus urethral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cystitis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Diabetic nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Haemorrhage urinary tract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hypertensive nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Micturition disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Nephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Polyuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Renal artery arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Renal artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Renal artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Renal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Renal hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Renal infarct</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Renal tubular necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Stress urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Ureteric dilatation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Ureteric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Urethral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Urinary bladder haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Urinary bladder polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Urinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Acquired phimosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Balanoposthitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cervix disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Menometrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Organic erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Perineal fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Prostatic disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Prostatism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Rectocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Sperm granuloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Spermatocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Uterovaginal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Alveolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Asthma late onset</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Dyspnoea paroxysmal nocturnal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Granulomatous pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hydrothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Laryngeal oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Nasal septum deviation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Obstructive airways disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pulmonary sarcoidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pulmonary thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Respiratory depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Sputum retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Diabetic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Dry gangrene</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Haemorrhage subcutaneous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pemphigus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Rosacea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Skin erosion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Stasis dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Toxic skin eruption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Coronary angioplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Coronary artery bypass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Percutaneous coronary intervention</sub_title>
                <counts group_id="E1" subjects_affected="252" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="262" subjects_at_risk="6452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Accelerated hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Angiodysplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm rupture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Aortic occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Aortic thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Arterial disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Arterial haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Arterial insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Arterial thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Coeliac artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Diabetic microangiopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Extremity necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Femoral artery aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Femoral artery dissection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Femoral artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Haemodynamic instability</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Iliac artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Iliac artery rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Ischaemic limb pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Jugular vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Leriche syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Lymphatic fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Lymphocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Malignant hypertension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Peripheral artery aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Peripheral artery dissection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Peripheral artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Peripheral artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Peripheral embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Polyarteritis nodosa</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Post thrombotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Reperfusion injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Subclavian artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Temporal arteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Vascular insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Vascular occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Vascular pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Vascular stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6452"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3416" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="3698" subjects_at_risk="6452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="187" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="184" subjects_at_risk="6452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="398" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="363" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="185" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="154" subjects_at_risk="6452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="130" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="140" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="128" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="135" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Abnormal faeces</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="525" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="174" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="165" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="351" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="675" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="116" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="130" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="130" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="127" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="176" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="198" subjects_at_risk="6452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="111" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="134" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="334" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="302" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="431" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="414" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="245" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="239" subjects_at_risk="6452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="178" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="192" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="143" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="141" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="279" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="273" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="144" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="162" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="205" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="157" subjects_at_risk="6452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="358" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="325" subjects_at_risk="6452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="207" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="158" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="262" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="224" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="130" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="98" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="186" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="215" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="221" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="181" subjects_at_risk="6452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="357" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="354" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="202" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="175" subjects_at_risk="6452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urine odour abnormal</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="344" subjects_at_risk="6452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="355" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="324" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="310" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="286" subjects_at_risk="6452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin odour abnormal</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="241" subjects_at_risk="6452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="409" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="370" subjects_at_risk="6452"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="132" subjects_at_risk="6465"/>
                <counts group_id="E2" subjects_affected="154" subjects_at_risk="6452"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

